Taxus Cardium Pharmaceuticals Group Inc. announced that Cardium Therapeutics will announce interim results on the Generx(R) angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Cardium will report on safety and efficacy data from the randomized, multi-center, controlled study's primary registration endpoint of improvement in microvascular cardiac perfusion (blood flow), with Generx compared to the control group in patients with cardiac microvascular insufficiency, which is based on a diagnosis of myocardial ischemia as measured by cardiac imaging. The ASPIRE clinical study represents the fifth clinical study under the Generx gene therapy worldwide development program, which when completed will have evaluated over 780 patients at over 100 medical centers in the United States, Western Europe, South America, Canada and the Russian Federation, and is considered the large cardiac gene therapy registration dossier in the world.